Phyla’s AI-enabled platform monitors digestive diseases using affordable stool microbiome testing and user-reported health information.

**BUSINESS CASE**

Gut disease affects 37 million North-Americans and represents $77B in annual healthcare spending. There is no cure for IBD and prognostics are poor.

**INSIGHTS**

IBD/IBS patients must endure: weak immunity, poor quality of life, repeat colonoscopies, vague diagnostics and frequent trips to the hospital.

**Phyla’s new approach to gut health monitoring: longitudinal data driven insights using both biological and self-reported sources**

Using the stool microbiome, our AI data processing pipeline can non-invasively detect IBD. This is then combined with user self-reported data from our digital health app (symptoms, medication compliance, diet, mood), we create a comprehensive data set comprising a longitudinal and holistic view of lifestyle, microbiome and patient outcomes. Data visualization allows us to show patients the links between their disease state, lifestyle, medication compliance and more. Using regular testing, personalized recommendations and educational materials, our platform will empower patients to take control of their disease by improving their disease understanding and quality of life.

**DATE OF CREATION**

April 1st 2020

**GEOGRAPHIC COVERAGE**

Canada, USA

**HQ LOCALIZATION**

Montreal, Québec, Canada

**FOUNDERS**

Lucca Cuccia, CEO
Ryszard Kubinski, CSO
Michael Golfi, CTO
Paul Godin, COO

**FUNDINGS**

$400k total

**INVESTORS**

Techstars Montreal AI 2019, MEDTEQ, La MAIN, Centech